Ranbaxy family faces huge tax outgoing in deal with Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' founding family faces the prospect of paying significant capital gains taxes after the Securities and Exchange Board of India (SEBI) rejected the company's plans to complete its sale of the company to Daiichi Sankyothrough a "block deal" on the bourses.